CPC C12N 15/86 (2013.01) [A61K 48/0058 (2013.01); C12N 2710/10043 (2013.01); C12N 2710/10343 (2013.01); C12N 2800/24 (2013.01)] | 6 Claims |
1. A pharmaceutical composition, comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding proteoglycan 4 (PRG4), or a biologically active fragment thereof, which has chondoprotective activity, a left and a right adenoviral inverted terminal repeats (L ITR and R ITR), adenoviral packaging signal sequences and non-viral, non-coding stuffer nucleic acid sequences,
wherein
i. the at least one helper-dependent adenoviral vector additionally comprises a nucleic acid sequence encoding interleukin-1 receptor antagonist (II-1Ra), or
ii the composition comprises a second helper-dependent adenoviral vector comprising a nucleic acid sequence encoding Il-1Ra;
wherein PRG4 expression is controlled by an elongation factor 1 alpha (EF 1 alpha) promoter and expression of Il-1Ra is controlled by an NF-κB promoter, and
wherein the at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding PRG4, comprises a nucleic acid sequence which has at least 90% sequence homology with the nucleic acid sequence set forth in SEQ ID NO: 1, or SEQ ID NO: 2.
|